Panitumumab-Associated Encephalopathy after Accidental Intra-arterial Application through Dislocated Central Venous Access Device.

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol (2010) 10.17

Complications after unintentional intra-arterial injection of drugs: risks, outcomes, and management strategies. Mayo Clin Proc (2005) 2.30

The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia (2009) 1.64

The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology (2003) 1.46

Global patterns and trends in colorectal cancer incidence and mortality. Gut (2016) 1.45

The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: the retrospective Berlin PRES study. J Neurol (2011) 1.39

Nonconvulsive status epilepticus related to posterior reversible leukoencephalopathy syndrome induced by cetuximab. Neurologist (2011) 0.91

Posterior reversible encephalopathy syndrome: a neurologic phenomenon in cancer patients. Curr Oncol Rep (2014) 0.89

Posterior Reversible Encephalopathy Syndrome Associated with FOLFOX Chemotherapy. Case Rep Oncol Med (2013) 0.89

Neurologic complications of electrolyte disturbances and acid-base balance. Handb Clin Neurol (2014) 0.88

Central role of the EGF receptor in neurometabolic aging. Int J Endocrinol (2012) 0.88

Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study. J Neurooncol (2016) 0.85

Posterior Reversible Encephalopathy Syndrome in Patients With Cancer. Oncologist (2015) 0.80

Port-a-Cath-related complications in 252 patients with solid tissue tumours and the first report of heparin-induced delayed hypersensitivity after Port-a-Cath heparinisation. Eur J Cancer Care (Engl) (2012) 0.79

Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials. Tumour Biol (2014) 0.79

Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies. Clin Colorectal Cancer (2015) 0.79

The safety of monoclonal antibodies for treatment of colorectal cancer. Expert Opin Drug Saf (2016) 0.79

Embolic stroke secondary to an indwelling catheter in a patient with a patent foramen ovale: a case report and review of the literature. Clin Adv Hematol Oncol (2012) 0.79

Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer. Onco Targets Ther (2012) 0.78

Posterior reversible encephalopathy syndrome (PRES) and hypomagnesemia: A frequent association? Rev Neurol (Paris) (2016) 0.78

Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer. Expert Opin Drug Metab Toxicol (2015) 0.78

Tocilizumab-associated multifocal cerebral thrombotic microangiopathy. Neurol Clin Pract (2016) 0.77

Seizure activity during cetuximab infusion in a patient with metastatic colorectal cancer. Am J Health Syst Pharm (2012) 0.77

Incidence of pulmonary embolism in patients with newly diagnosed colorectal cancer. ANZ J Surg (2016) 0.77